MeiraGTx vs Intellia Therapeutics
MeiraGTx reported revenue of $81 million in fiscal 2025, 1.2 times Intellia Therapeutics' $68 million in fiscal 2025. MeiraGTx's revenue grew 144.6% in its latest year, and Intellia Therapeutics' grew 16.9%. MeiraGTx had an operating margin of -130.2%, against -651.7% at Intellia Therapeutics. Free cash flow was −$50 million at MeiraGTx and −$396 million at Intellia Therapeutics.
Side by side
| MeiraGTx | Intellia Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $81M | $68M |
| Revenue growth | 144.6% | 16.9% |
| Revenue growth a year, last 5 years | 39.2% | 3.1% |
| Gross margin | — | — |
| Operating margin | −130.2% | −651.7% |
| Net margin | −140.3% | −609.9% |
| Free cash flow | −$50M | −$396M |
| Free cash flow margin | −61.7% | −585.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.2% | 9.6% |
| Last close | $9.18 | $9.70 |
| P/E at the last close | 11.5× | — |
| Insider trades, last 12 months | — | bought $1.4 million, sold $2.1 million |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MeiraGTxIntellia Therapeutics
Operating margin
Percent of revenue
MeiraGTxIntellia Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MeiraGTxIntellia Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MeiraGTx and Intellia Therapeutics pages.